Eli Lilly and Company (BIT:1LLY)

Market Cap	491.72B
Revenue (ttm)	45.35B
Net Income (ttm)	11.75B
Shares Out	n/a
EPS (ttm)	13.02
PE Ratio	41.85
Forward PE	23.32
Dividend	5.20 (0.93%)
Ex-Dividend Date	May 15, 2025

Volume	2,448
Average Volume	778
Open	541.00
Previous Close	540.20
Day's Range	538.00 - 562.40
52-Week Range	535.20 - 888.00
Beta	n/a
RSI	26.64
Earnings Date	Aug 7, 2025

About Ligand Pharmaceuticals

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.